Association for Molecular Pathology

A medical subspecialty professional society

Based in MD

🤖

AI Overview

With $1.5M in lobbying spend across 30 quarterly filings, Association for Molecular Pathology is a significant lobbying presence. Their lobbying covers 6 issue areas. Active from 2019 to 2025.

$1.5M
Total Spend
7
Years Active
1
Firms Hired
4
Lobbyists Deployed
6
Issues Lobbied

Spending Trend

View as table
YearLobbying Spend
2019$150K
2020$150K
2021$168K
2022$252K
2023$210K
2024$282K
2025$282K

Issues Lobbied

Lobbying Firms

Lobbyists

Government Agencies Targeted

These are the government entities that Association for Molecular Pathology disclosed contacting in their lobbying filings.

Centers For Medicare and Medicaid Services (CMS)HOUSE OF REPRESENTATIVESSENATEFood & Drug Administration (FDA)Centers For Disease Control & Prevention (CDC)Natl Institutes of Health (NIH)Office of Science & Technology Policy (OSTP)Government Accountability Office (GAO)Federal Trade Commission (FTC)Office of Management & Budget (OMB)Health & Human Services, Dept of (HHS)
View all agency pressure data →

What They Lobby About

These are actual descriptions from their quarterly lobbying disclosure filings, summarizing what they lobbied Congress and federal agencies about.Issue areas: MED, Health Issues, Medicare/Medicaid, Copyright/Patent, Consumer Issues and 1 more

No bill #, Verifying Accurate Leading-Edge IVCT Development (VALID) Act

Coverage and reimbursement for molecular diagnostics

Medicare coverage of next generation sequencing based tests for cancer

No bill #, Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage

No bill #, reform Sec. 101 of the Patent Act

Related Analysis

Related Investigations

Similar Clients

Explore More

Data Sources: Senate LDA Filings

Last updated: February 2026

This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.